Silence Therapeutics (SLN) Other Non-Current Assets (2023 - 2026)

Silence Therapeutics (SLN) posted Other Non-Current Assets of $127000.0 for Q1 2026, little changed sequentially from $127000.0 in Q4 2025, and down 96.49% YoY from $3.6 million in Q1 2025.

Silence Therapeutics (SLN) Other Non-Current Assets (2023 - 2026) Analysis & Trends

Silence Therapeutics has reported Other Non-Current Assets for 4 years, with the latest figure at $127000.0 in Q1 2026.

  • Quarterly Other Non-Current Assets fell 96.49% year-over-year to $127000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127000.0 (down 96.49% YoY) and the FY2025 annual result came in at $127000.0, down 96.46% from the prior year.
  • Other Non-Current Assets steadied at $127000.0 in Q1 2026 per SLN's latest filing, from $127000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $3.9 million in Q2 2025 and troughed at $127000.0 in Q4 2025.
  • A 4-year average of $2.1 million and a median of $3.2 million in 2023 frame the typical range for Other Non-Current Assets.
  • The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets gained 12.11% in 2024, then plunged 96.49% in 2026.
  • Over 4 years, Other Non-Current Assets stood at $3.2 million in 2023, then grew by 12.11% to $3.6 million in 2024, then sank by 96.46% to $127000.0 in 2025, then changed by 0.0% to $127000.0 in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $127000.0, $127000.0, and $399000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 2.31 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 124.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 42.45 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 109.58 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 18,237.65
7 Royalty Pharma 33.72 Bn 35.84 Bn - 62.96 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 65.13 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 104.44 Mn
10 Silence Therapeutics 648.22 Mn 576.12 Mn - 127,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 127,000.00
Mar 31, 2026 127,000.00
Dec 31, 2025 127,000.00
Sep 30, 2025 399,000.00
Jun 30, 2025 3.91 Mn
Mar 31, 2025 3.61 Mn
Dec 31, 2024 3.59 Mn
Dec 31, 2023 3.20 Mn